TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33780099

Group type: EXPERIMENTAL
Intervention: Chronic disease management mode (CDMM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 300
Study: 33126931

Group type: EXPERIMENTAL
Intervention: Intervention involving in-service training provided by nurses, work process organisation, and additional clinic-specific solutions in six clinics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive initial and subsequent in-service training provided by a physician in two clinics.
Number of subjects: 0
Study: 34036820

Group type: EXPERIMENTAL
Intervention: Videoconferenced yoga sessions
Number of subjects: 7

Group type: COMPARATOR
Intervention: In-person yoga sessions
Number of subjects: 7
Study: 32692216

Group type: EXPERIMENTAL
Intervention: Modified Dachengqi decoction combined with conventional therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 34271307

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 72
Study: 33087178

Group type: EXPERIMENTAL
Intervention: 7-session online cognitive behavioral therapy (CBT) program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bibliotherapy (active control)
Number of subjects: 120
Study: 33601921

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4204

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 4204

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4204

Group type: EXPERIMENTAL
Intervention: Aspirin, Enoxaparin, Warfarin
Number of subjects: 4204
Study: 33001334

Group type: EXPERIMENTAL
Intervention: Outreach encouraging MOP use (mailed letter, secure email message, automated telephone call)
Number of subjects: 63012

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 63012
Study: 33758499

Group type: EXPERIMENTAL
Intervention: Test drug (90 mg ticagrelor tablets) under fasting conditions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Test drug (90 mg ticagrelor tablets) under fed conditions
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reference drug (90 mg ticagrelor tablets) under fasting conditions
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reference drug (90 mg ticagrelor tablets) under fed conditions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both test and reference drugs
Number of subjects: 80
Study: 32876408

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study: 35385076

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36459768

Group type: EXPERIMENTAL
Intervention: Vorolanib plus everolimus
Number of subjects: 399

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Vorolanib
Number of subjects: 399
Study: 33586526

Group type: EXPERIMENTAL
Intervention: ESWT point
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ESWT line
Number of subjects: 66

Group type: COMPARATOR
Intervention: ESWT placebo
Number of subjects: 66
Study: 33826785

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg twice daily for three months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid combined with topical hydroquinone 4% cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid combined with two sessions of 1064 nm low-fluence Q-switched Nd:YAG laser
Number of subjects: 60
Study: 33568137

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl (Actellic®300 CS)
Number of subjects: 1536
Study: 35195481

Group type: EXPERIMENTAL
Intervention: Community support workers (CSWs) providing HIV health education, personal counseling, and social support for HIV patients.
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1799
Study: 34214305

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (100% O2 at 2.4 ATA for 3 × 30 min with intervals of 2 × 5 min for inhaling fresh air, once a day for 5 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normoxia normobaric - NONB, 20% O2 at 1 ATA for 90 min)
Number of subjects: 32
Study: 32033908

Group type: EXPERIMENTAL
Intervention: Palucorcel (3.0 × 10^5 cells in 50 μl) administered via subretinal injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 21
Study: 32876714

Group type: EXPERIMENTAL
Intervention: Pudendal block with ropivacaine 7.5 mg/ml
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 41
Study: 32251064

Group type: EXPERIMENTAL
Intervention: New method for estimating randomized natural direct effect (rNDE) and randomized natural indirect effect (rNIE) using regression methods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear model for the conditional mean of the mediator given treatment and baseline confounders.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear model for the conditional mean of the outcome given treatment, mediator, and confounders.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education as a treatment variable.
Number of subjects: 0
Study: 34321432

Group type: EXPERIMENTAL
Intervention: Immediate mobilization (IM)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Bed rest (BR) for 2 hours
Number of subjects: 2027
Study: 33438372

Group type: EXPERIMENTAL
Intervention: Urine EtG dipstick at threshold of 1000 ng/mL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urine EtG dipstick at threshold of 1500 ng/mL
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mass spectrometry (gold standard)
Number of subjects: 12
Study: 36227235

Group type: EXPERIMENTAL
Intervention: 5-point facial RPE scale (FCR5)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 10-point facial RPE scale (FCR10)
Number of subjects: 49

Group type: COMPARATOR
Intervention: CR10 (Borg's category‐ratio 10‐point scale)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: FCR10
Number of subjects: 49
Study: 33967056

Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active Control (CON)
Number of subjects: 70
Study: 33036701

Group type: EXPERIMENTAL
Intervention: MI plus ω‐3 (800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid/day)
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: MI alone
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation alone
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 1445
Study: 33141278

Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided mapping biopsy (CMB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluoroscopy-guided mapping biopsy (FMB)
Number of subjects: 28
Study: 32374900

Group type: EXPERIMENTAL
Intervention: Ready-to-eat vegetable salads
Number of subjects: 0
Study: 34961699

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection (4 mg/0.1 ml) into the upper eyelid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (fellow eyelid not injected)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection
Number of subjects: 32
Study: 33546963

Group type: EXPERIMENTAL
Intervention: Povidone iodine-based rigid lens disinfecting solution
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cleaning routines with and without daily and/or weekly cleaners
Number of subjects: 76
Study: 32388538

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34644189

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study: 34749549

Group type: EXPERIMENTAL
Intervention: Functional high-intensity interval training (F-HIIT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combined training (CT)
Number of subjects: 49
Study: 34237979

Group type: EXPERIMENTAL
Intervention: Group C (Foley1m+IUD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Group A (IUD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Group B (Foley1w+IUD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study: 32573956

Group type: EXPERIMENTAL
Intervention: TAS-303 8-18 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35439461

Group type: EXPERIMENTAL
Intervention: Resilience training (eight-week resilience training; n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wait-list control group (eight-week health education; n = 34)
Number of subjects: 68
Study: 33030881

Group type: EXPERIMENTAL
Intervention: Oral misoprostol plus Foley bulb (100 micrograms)
Number of subjects: 2237

Group type: COMPARATOR
Intervention: Oral misoprostol alone (100 micrograms)
Number of subjects: 2237
Study: 36109766

Group type: EXPERIMENTAL
Intervention: RDT decisional algorithm (RDT-DA) arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-algorithm arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (IMCI standard of care)
Number of subjects: 0
Study: 33706770

Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Technical Assistance (TA)
Number of subjects: 48
Study: 32579812

Group type: EXPERIMENTAL
Intervention: Intervention schedules (16 hours or less shifts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schedules (24 hours or more shifts)
Number of subjects: 0
Study: 35211010

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine at 0.8 μg.kg−1 for 10 min
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg.kg−1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine at 4 μg.kg−1
Number of subjects: 45
Study: 33188392

Group type: COMPARATOR
Intervention: Dietary concentration of ergovaline: 0, 0.862, and 1.282 mg/kg of diet (experiment 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Endophyte-infected seeds providing ergovaline dosage of 15 μg/kg BW (experiment 2)
Number of subjects: 16
Study: 33509602

Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 75 mm Hg (group I)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 100 mm Hg (group II)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 150 mm Hg (group III)
Number of subjects: 150
Study: 32568429

Group type: EXPERIMENTAL
Intervention: Abnormal FEF75
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Very abnormal FEF75
Number of subjects: 126
Study: 35857196

Group type: EXPERIMENTAL
Intervention: Mirogabalin and NSAIDs
Number of subjects: 220

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 220
Study: 33793734

Group type: EXPERIMENTAL
Intervention: Immediate total-body CT (iTBCT)
Number of subjects: 928

Group type: COMPARATOR
Intervention: Standard work-up (STWU)
Number of subjects: 928
Study: 35246418

Group type: EXPERIMENTAL
Intervention: Axial tumour site
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Poor histological response
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Age <12 years
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Age >18 years
Number of subjects: 1631
Study: 33313847

Group type: EXPERIMENTAL
Intervention: MISTIE procedure with recombinant tissue plasminogen activator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis for large intraventricular hemorrhage
Number of subjects: 0
Study: 35150143

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (160 mg for 10 days)
Number of subjects: 14
Study: 33306635

Group type: EXPERIMENTAL
Intervention: Digital PET/CT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Analog PET/CT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 64
Study: 32890472

Group type: EXPERIMENTAL
Intervention: aPDT + LLLT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: aPDT group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LLLT group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: aPDT + LLLT group
Number of subjects: 40
Study: 36199630

Group type: COMPARATOR
Intervention: 0.5 mg/kg lidocaine (L0.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg lidocaine (L1.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine (L1.5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: saline (L0)
Number of subjects: 0
Study: 32572778

Group type: EXPERIMENTAL
Intervention: Citrus aurantium essential oil inhalation for 15–20 min about 60 min before angiography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Distilled water inhalation (control group)
Number of subjects: 80
Study: 32893372

Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically elevated body mass index (BMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher CRP concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study: 35798988

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n = 172)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care (n = 172)
Number of subjects: 344
Study: 32768315

Group type: EXPERIMENTAL
Intervention: High EAA (0.3 g/kg, 23.5 ± 2.54 g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard EAA (0.1 g/kg, 7.87 ± 0.87 g)
Number of subjects: 19
Study: 35917753

Group type: EXPERIMENTAL
Intervention: Developmentally Adapted Cognitive Processing Therapy (D-CPT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist with treatment advice (WL/TA)
Number of subjects: 44
Study: 33727428

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Itopride
Number of subjects: 60

Group type: COMPARATOR
Intervention: CEPS patients
Number of subjects: 60
Study: 36104971

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (FA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-intensity 60-minute FA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 60-minute FA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate intensity FA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30-minute low-intensity FA
Number of subjects: 26
Study: 33626021

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 120

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stress ball
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 33183660

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIpostC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham remote ischemic postconditioning
Number of subjects: 106
Study: 35351054

Group type: EXPERIMENTAL
Intervention: KiVa anti-bullying programme
Number of subjects: 13000

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 13000
Study: 33610906

Group type: EXPERIMENTAL
Intervention: Compassionate Focused Therapy (CFT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 74

Group type: COMPARATOR
Intervention: PTSD
Number of subjects: 74

Group type: COMPARATOR
Intervention: CPTSD
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traumatic stress
Number of subjects: 74
Study: 36445384

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 2163
Study: 35106332

Group type: EXPERIMENTAL
Intervention: Dynamic Hip External Fixator (DHEF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 46
Study: 35428718

Group type: EXPERIMENTAL
Intervention: MTX+ETN combination therapy
Number of subjects: 851
Study: 33750279

Group type: EXPERIMENTAL
Intervention: Trust in research physicians
Number of subjects: 229

Group type: COMPARATOR
Intervention: Trust in primary care providers
Number of subjects: 229

Group type: COMPARATOR
Intervention: Trust in medical research processes
Number of subjects: 229
Study: 32843021

Group type: EXPERIMENTAL
Intervention: Holidaily app intervention (IG) - two weeks pre-vacation access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist-control group (CG) - access to Holidaily two weeks post-vacation
Number of subjects: 0
Study: 35232782

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 622
Study: 33442924

Group type: COMPARATOR
Intervention: Bilateral formula-based ECT (BT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Right unilateral formula-based ECT (RUL)
Number of subjects: 29
Study: 36074703

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted carbon nanoparticle suspension (CNS) mapping
Number of subjects: 330

Group type: COMPARATOR
Intervention: Dual tracer-guided mapping with CNS plus indocyanine green (ICG)
Number of subjects: 330
Study: 35421019

Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) supplement for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46
Study: 32143716

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POMj)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study: 34719994

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 33074284

Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 15 mg daily
Number of subjects: 3699

Group type: COMPARATOR
Intervention: Aspirin, 100 mg daily
Number of subjects: 3699
Study: 34967184

Group type: EXPERIMENTAL
Intervention: Vitamin D with physical activity (VDPA arm)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vitamin D alone (VD arm)
Number of subjects: 46
Study: 33570584

Group type: EXPERIMENTAL
Intervention: Peripheral age-related hearing loss (ARHL) in the physical frailty group (96 out of 361, 26.6%)
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Peripheral age-related hearing loss (ARHL) in the cognitive frailty group (40 out of 103, 38.8%)
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Age-related central auditory processing disorder (CAPD) in the physical frailty group (62 out of 361, 17.2%)
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Age-related central auditory processing disorder (CAPD) in the cognitive frailty group (28 out of 103, 27.2%)
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Age-related CAPD
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Synthetic Sentence Identification With the Ipsilateral Competitive Message scores
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Peripheral ARHL
Number of subjects: 1929
Study: 32065623

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg zilucoplan SC daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg zilucoplan SC daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg zilucoplan
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg zilucoplan
Number of subjects: 44
Study: 33474611

Group type: EXPERIMENTAL
Intervention: IVT‐AFL
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: IVT‐AFL + rPDT
Number of subjects: 159
Study: 34662341

Group type: EXPERIMENTAL
Intervention: Information structuring (S)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Empathy (E)
Number of subjects: 256
Study: 33306586

Group type: EXPERIMENTAL
Intervention: Whole eggs + RT (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Egg whites + RT (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole eggs + RT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Egg whites + RT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 32285955

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg dose)
Number of subjects: 133
Study: 35197100

Group type: EXPERIMENTAL
Intervention: Integrated CMCA-Connect intervention
Number of subjects: 20
Study: 35942408

Group type: EXPERIMENTAL
Intervention: Nivolumab plus split-course radiotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 44
Study: 35257648

Group type: EXPERIMENTAL
Intervention: digital cognitive behavioral therapy for insomnia (dCBT-I)
Number of subjects: 658

Group type: COMPARATOR
Intervention: sleep education control
Number of subjects: 658
Study: 33546067

Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI) training, performed at home for 8 weeks, 30 minutes a day.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 42
Study: 32932175

Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 0

Group type: COMPARATOR
Intervention: GBCM-exposed RBCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: GBCM-exposed K562 cancer cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: GBCM (all three types)
Number of subjects: 0
Study: 36066179

Group type: EXPERIMENTAL
Intervention: Flexible tip bougie
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard bougie
Number of subjects: 160
Study: 33387920

Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Social jetlag
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chronotype
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Time interval >2 h between last meal and sleep onset
Number of subjects: 36
Study: 35788070

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (daily tablet for 6 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (daily tablet for 6 months)
Number of subjects: 140
Study: 33620905

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (100 mg) twice-daily for 5 days
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo twice-daily for 5 days
Number of subjects: 164